Home > News > Calando to Jointly Develop RNAi Therapeutics
February 3rd, 2006
Calando to Jointly Develop RNAi Therapeutics
Abstract:
Arrowhead Research Corporation (Nasdaq:ARWR) announced today that its majority-owned subsidiary Calando Pharmaceuticals, Inc. and the National Cancer Institute (NCI) have established a collaborative development program to develop RNA interference (RNAi) therapeutics to fight a form of childhood cancer. Calando's self-assembling RNAi therapeutic nanoparticle contains linear cyclodextrin (a form of sugar), an siRNA and a targeting molecule.
Source:
businesswire
Related News Press |
Possible Futures
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
Nanomedicine
Multiphoton polymerization: A promising technology for precision medicine February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
SMART researchers pioneer first-of-its-kind nanosensor for real-time iron detection in plants February 28th, 2025
Materials/Metamaterials/Magnetoresistance
Chainmail-like material could be the future of armor: First 2D mechanically interlocked polymer exhibits exceptional flexibility and strength January 17th, 2025
Enhancing transverse thermoelectric conversion performance in magnetic materials with tilted structural design: A new approach to developing practical thermoelectric technologies December 13th, 2024
FSU researchers develop new methods to generate and improve magnetism of 2D materials December 13th, 2024
Announcements
Closing the gaps — MXene-coating filters can enhance performance and reusability February 28th, 2025
Rice researchers harness gravity to create low-cost device for rapid cell analysis February 28th, 2025
![]() |
||
![]() |
||
The latest news from around the world, FREE | ||
![]() |
![]() |
||
Premium Products | ||
![]() |
||
Only the news you want to read!
Learn More |
||
![]() |
||
Full-service, expert consulting
Learn More |
||
![]() |